C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 207/09 (2006.01) A61K 31/40 (2006.01) A61K 31/435 (2006.01) A61P 25/00 (2006.01) C07D 401/14 (2006.01)
Patent
CA 2600757
The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods and intermediates for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.
La présente invention porte sur de nouveaux composés de formule (I) ou leurs sels acceptables sur un plan pharmaceutique qui ont un antagoniste de récepteur H3 de l~histamine ou une activité agoniste inverse, de même que des procédés et intermédiaires pour la préparation de tels composés. Dans un autre mode de réalisation, l~invention concerne des compositions pharmaceutiques comprenant des composés de formule (I) de même que des procédés d~utilisation de ceux-ci pour traiter l~obésité, les déficiences cognitives, la narcolepsie, et d~autres maladies liées au récepteur H3 de l~histamine.
Beavers Lisa Selsam
Finley Don Richard
Gadski Robert Alan
Hipskind Philip Arthur
Jesudason Cynthia Darshini
Eli Lilly And Company
Gowling Lafleur Henderson Llp
LandOfFree
Pyrrolidine derivatives as histamine h3 receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrrolidine derivatives as histamine h3 receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrolidine derivatives as histamine h3 receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1469003